JPJosé María Pego-Reigosa

José María Pego-Reigosa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


José María Pego-Reigosa has a total of 559 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Disease activity and patient‐perceived health: associations with the Patient Acceptable Symptom State (PASS) in a large multicenter systemic lupus erythematosus cohort

    by César Magro‐Checa, Sofia Ramiro, Hanna Kenjić, José M. Pego‐Reigosa, María Galindo‐Izquierdo, Zulema Plaza, Julia Martínez‐Barrio, Esther Rodríguez‐Almaraz, Jaime Calvo‐Alen, Natalia Mena‐Vazquez, et al.

    Objective: We aimed to evaluate the relationship between disease activity and the Patient Acceptable Symptom State (PASS) and to identify clinical and socio‐demographic factors associated with PASS in systemic lupus erythematosus (SLE). Methods: We analyzed data from the Spanish multicenter SLE registry (RELESSER). PASS was self‐reported. Disease activity was assessed using SLEDAI‐2K and targeted disease activity states (DORIS remission and LLDAS). Collected variables included socio‐demographic factors (age, sex, employment, educational attainment), fibromyalgia, organ damage (SDI), current therapies and the Lupus Impact Tracker (LIT). Associations with PASS were analyzed for each disease activity state measure by univariable and multivariable logistic regression. A subgroup analysis was performed in patients in DORIS remission. Results: 72% of patients (n=1249) reported being in PASS. Lower SLEDAI‐2K, DORIS remission and LLDAS were independently associated with being in PASS. Higher education level and being employed were positively associated, while female sex and fibromyalgia were negatively associated with PASS. After including LIT items in the models, DORIS remission and LLDAS remained associated, while pain, fatigue‐related limitations and anxiety showed the strongest associations. Among patients in DORIS remission, 20% were not in PASS, with female sex, fibromyalgia, pain, fatigue‐related limitations and anxiety remaining independent barriers. Conclusion: DORIS remission and LLDAS are associated with PASS, supporting their relevance as treatment targets from the patient's perspective. Pain, fatigue and anxiety hinder many patients with SLE from achieving satisfactory health beyond disease remission. One in five patients in remission is still not in PASS. PASS assessment may help capture unmet needs in SLE management. image

  • Open Access

    Sema4A neutralization reduces fibrosis and inflammation in a mouse model of systemic sclerosis and a 3D model of immunity‐driven fibrosis

    by Jaime Marty, Sara Martinez‐Ramos, Carlos Rafael‐Vidal, Beatriz Malvar‐Fernández, Tiago Carvalheiro, Ralph G. Tieland, Ines Ramos, Wiola Marut, Ana Pinheiro‐Lopes, Ana Argibay, et al.

     Objective: We previously showed that Semaphorin4A (Sema4A) is elevated in patients with systemic sclerosis (SSc) and promotes inflammation and fibrosis in vitro . Here, we examined the effect of Sema4A neutralization in vivo and in 3D fibrosis models. Methods: Sema4A plasma levels were measured by ELISA in healthy controls (n=31) and patients with SSc (n=30). In the bleomycin SSc‐model, mice were treated with an anti‐Sema4A neutralizing antibody or its respective isotype control (n=6‐7). The 3D fibrosis models, consisting of collagen hydrogel, dermal fibroblasts, and peripheral blood mononuclear cells, were stimulated with recombinant Sema4A, rapamycin, or antibodies neutralizing Sema4A, PlexinD1, PlexinB2, Neuropilin‐1 or their respective isotype controls (n=6‐10). Collagen content was determined by trichrome staining and hydroxyproline assay. Gene expression was determined by RT‐qPCR and obtained from GEO‐NCBI expression arrays, while protein expression by immunohistochemistry, immunoblotting and flow cytometry. Results: Circulating Sema4A was elevated in patients with SSc (p<0.0001), while Sema4A receptors were elevated in SSc skin and lung (p ranged from <0.05 to 0.0001). Anti‐Sema4A administration significantly reduced skin and lung collagen content in bleomycin‐treated mice (p<0.01), as well as the expression of extracellular matrix components, fibrotic and inflammatory mediators, and immune cell infiltration. In the 3D models, SSc serum and SSc PBMCs induced cell contraction, which was drastically abrogated by blocking Sema4A (p<0.01). This effect was associated with reduced expression of fibrotic mediators and attenuated mTORC1 pathway activation. Conclusions: We confirmed the pro‐fibrotic and pro‐inflammatory role of Sema4A, postulating Sema4A neutralization as a novel approach for the treatment of SSc.

  • Open Access

    Real-world treatment patterns and outcomes in moderate-to-severe SLE: findings from the Spanish SPOCS cohort

    by Nuria Lozano-Rivas, Iñigo Rúa-Figueroa, Mercedes Freire-González, Ana Turrión, Iván Castellvi, Julia Barbado Ajo, Jaime Calvo-Alén, Norberto Ortego-Centeno, Monserrat Díaz-Encarnación, José María Pego-Reigosa, et al.

    Objective: This analysis describes disease activity, organ damage and health-related quality of life (HRQoL) in patients with active SLE and moderate-to-severe disease activity from the Spanish SLE Prospective Observational Cohort Study (SPOCS) cohort. Methods: SPOCS ( NCT03189875 ) is a multicentre, prospective, observational cohort that followed-up adults with SLE every 6 months for up to 3 years. Disease activity was assessed using SLE Disease Activity Index 2000 (SLEDAI-2K) and Physician Global Assessment. Remission and Lupus Low Disease Activity State (LLDAS) definitions were therapeutic objectives; organ damage by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI); HRQoL by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Patient Health Questionnaire-8 (PHQ-8) and EuroQol 5-Dimension 5-Level (EQ-5D-5L). Patients were recruited from 18 Spanish sites (2017–2019). Results: 99 patients were enrolled. At baseline, median (IQR) SLEDAI-2K was 8 (7-12); 45% of patients had organ damage (mean (SD) SDI 1.1 (1.6)). Remission was achieved by 13% at 6 months and at 24 months; sustained remission occurred in 9%. 24% achieved LLDAS at 6 months and ≤22% thereafter; 8% maintained LLDAS for ≥70% of follow-up. Median SLEDAI-2K declined to 4 at 6 months. New or worsening organ damage occurred in 11%, 8% and 12% of patients at 12, 24 and 36 months, respectively; mean SDI (SD) increased to 1.8 (2.0) by 36 months. Musculoskeletal, cutaneous, neuropsychiatric and renal systems were most frequently involved. HRQoL remained poor: 60%–75% had depressive symptoms (PHQ-8 ≥5), 35%–50% moderate-to-severe depression (PHQ-8 ≥10), mean FACIT-F ≈30 (indicating persistent severe fatigue) and mean EQ-5D-5L index 0.70–0.75. Pain/discomfort affected up to 76% and anxiety/depression up to 66% of participants. Conclusions: In Spanish clinical practice, sustained remission and low disease activity state remain uncommon in moderate-to-severe SLE. Nearly half had organ damage at baseline, with continued accrual and impaired HRQoL. These findings highlight ongoing challenges in achieving lasting disease control and underscore the need for broader adoption of treat-to-target approaches to improve outcomes and prevent irreversible organ damage in this patient population. Trial registration number: NCT03189875 .


  • Open Access

    Demographic and clinical characteristics of patients with systemic lupus erythematosus across five registries: the LupusNet federated data network

    by Federico Zazzetti, Ashley Orillion, Urbano Sbarigia, Anna Sheahan, Clair Blacketer, Michel van Speybroeck, Sarah Gasman, Reyhan Sönmez, Erika H Noss, Manuel F Ugarte-Gil, et al.

    Objective: This study describes baseline demographics, clinical characteristics and treatments of patients diagnosed with systemic lupus erythematosus (SLE) at the time of registration in the registries of the Lupus Federated Data Network (LupusNet). Methods: Data were collected from five SLE registries in four global regions: APLC (Asia Pacific), FORWARD (North America), RELESSER (Europe), GLADEL 2.0 and Almenara (Latin America). LupusNet uses a federated data network approach and a privacy-by-design method, where only aggregated results are shared. Demographics, disease activity (based on Physician Global Assessment (PGA) and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores), accumulated damage (Systemic Lupus International Collaborating Clinics Damage Index) and treatment use data were mapped and harmonised using the Observational Medical Outcomes Partnership Common Data Model V.5.4. Results: A total of 10 370 patients were included in the analysis; of those, 3908 patients were in Asia Pacific, 3066 in North America, 1806 in Europe and 1590 in Latin America. The majority of patients were female (91%); the median (IQR) duration from SLE diagnosis to registry entry ranged from 5 (1–12) to 12 (6–19) years. Heterogeneity in disease activity was observed across registries based on mean (SD) SLEDAI-2K total (3.0 (4.1)−7.0 (7.4)) and PGA (0.4 (0.5)−1.2 (1.0)) scores. Across registries, SLE features most common were related to serologic activity (low complement and increased DNA binding (19%–47%)); other common clinical features included proteinuria and arthritis (4%–37%). Cataracts (4%–9%) were the most common characteristic related to accumulated damage. Glucocorticoids, antimalarials and immunosuppressants were the most commonly used treatments, with variations in their proportions observed across registries. Conclusions: These findings demonstrate significant heterogeneity in clinical characteristics and treatment patterns across the registries in LupusNet. By recognising regional differences, findings from LupusNet may help guide treatment approaches in SLE and optimise patient outcomes.


  • Does adding concomitant immunosuppressive therapy to belimumab provide additional benefits in SLE? Results from the BEL-Spain Registry

    by Beatriz Frade-Sosa, José A Gómez-Puerta, Irene Altabás-González, José María Pego-Reigosa, Ivette Casafont-Solé, Tarek Carlos Salman-Monte, Andrea Hernández-Martín, José Andrés Román-Ivorra, María Piqueras-García, Sandra Garrote-Corral, et al.

    Objectives: Belimumab (BEL) is an approved biologic therapy for systemic lupus erythematosus (SLE) that, when added to standard care, reduces disease activity, flare rates and glucocorticoid exposure. In clinical practice, BEL is frequently combined with conventional immunosuppressants (IS), but the added benefit of concomitant IS once disease control is achieved remains uncertain. Observational data suggest that BEL monotherapy may be effective in selected patients, but comparative real-world evidence is limited. Objectives were to evaluate the clinical effectiveness of BEL as monotherapy vs in combination with IS in patients with SLE included in the BEL-Spain Registry. Methods: We performed a retrospective analysis of SLE patients treated with BEL with or without IS, with at least 12 months of follow-up. The primary outcome was remission according to the 2021 DORIS definition. Secondary outcomes included Lupus Low Disease Activity State (LLDAS), flare rates and glucocorticoid use. Overlap propensity score weighting was applied to adjust for confounding by indication. Results: Among 258 patients, 177 (68.6%) received BEL with IS and 81 (31.4%) BEL monotherapy. At 12 months, DORIS remission rates were 48.1% in the IS group and 51.4% in the monotherapy group (P=NS), with comparable LLDAS and flare rates. Propensity score-adjusted analyses confirmed no significant differences in remission rates (OR 0.89, 95% CI 0.37–2.14). Global treatment trajectories were stable, other than progressive glucocorticoid reduction in both groups. Conclusion: In this real-world cohort, BEL monotherapy achieved similar outcomes to combination therapy with IS in selected SLE patients. Prospective studies are needed to confirm these findings and define optimal treatment strategies.

  • Top Cited Papers
    Open Access

    Real-world experience with belimumab-based triple therapy in proliferative lupus nephritis: data from the BEL-SPAIN Registry

    by Paola Vidal-Montal, Aina Fabregat, Irene Altabás-González, José María Pego-Reigosa, Andrea Hernández-Martínez, Iñigo Rua-Figueroa, Tarek Salman-Monte, Clara Moriano, Beatriz Tejera Segura, Paloma Vela, et al.

    Objective: To evaluate the efficacy, safety and predictive factors of belimumab (BEL)-based triple therapy in proliferative lupus nephritis (LN) in real-world settings. Methods: We conducted a multicentre, retrospective study including patients with proliferative LN (new-onset or relapsing) who initiated BEL within 6 months of a renal flare, in combination with standard-of-care. Results: 49 patients were included (mean age 37 years; 85.7% female; 67.3% Caucasian). The median time from renal flare to BEL initiation was 1 month (IQR 0–3). By 12 months, 67.3% achieved complete renal response (CRR), 75.5% primary efficacy renal response (PERR) and 83.7% at least partial renal response. Median proteinuria declined from 2.7 g/day to 0.49 g/day, with parallel improvement in estimated glomerular filtration rate (71 to 78 mL/min/1.73 m²). Patients with baseline proteinuria <3 g/day achieved significantly higher CRR (78.1% vs 47.1%; p=0.027) and PERR (84.4% vs 58.8%; p=0.048) rates. The mean glucocorticoid (GC) dose decreased from 31.7 mg/day at baseline to 3.5 mg/day at 12 months, and 26.1% of patients achieved complete GC withdrawal. Extrarenal disease activity was present in 81.6% of patients at baseline, predominantly articular and mucocutaneous, with clinically meaningful improvement in 80% during follow-up. At 12 months, 40.8% met remission by Definition Of Remission In Systemic Lupus Erythematosus (DORIS) criteria and 46.9% attained Lupus Low Disease Activity State (LLDAS). Renal treatment failure occurred in 16.3% and renal relapse in 4.1%. Adverse events were mild, and no serious BEL-related events were observed. Conclusion: BEL-based triple therapy is effective and safe in proliferative LN, achieving high renal and extrarenal response rates, substantial GC-sparing and treat-to-target outcomes in real-world practice.


  • Open Access

    Self-reported depression on the Lupus Impact Tracker questionnaire (LIT) is associated with glucocorticoid use and fibromyalgia in systemic lupus erythematosus, according to RELESSER-PROS registry data

    by Inigo Rua-Figueroa, Julia Martínez-Barrio, Zulema Plaza, Norman Jiménez, Maria Galindo-Izquierdo, Esther Uriarte, Antonio Fernandez-Nebro, Jaime Calvo Alen, José Rosas, Javier Narváez, et al.

    To assess the prevalence and persistence of self-reported depression and its associated factors in patients with systemic lupus erythematosus (SLE), using

  • Open Access

    Oral glucocorticoid patterns use in moderate to severe active SLE: insights from the Spanish SPOCS data

    by Iñigo Rua-Figueroa, Ricard Cervera, Mercedes Freire-González, Ana Isabel Turrión Nieves, Josefina Cortés-Hernández, Iván Castellvi, Julia Barbado Ajo, Tarek Salman, Jaime Calvo Alén, Nuria Lozano-Rivas, et al.

    The unpredictable nature of the SLE disease activity makes its management particularly challenging. Current treatment options for SLE focus on managing the inflammatory status, decreasing the symptoms and reducing the frequency and severity of flares. Glucocorticoids (GCs) are a common and still essential treatment for SLE due to their rapid and potent anti-inflammatory and immunosuppressive effects. However, prolonged GC use is linked to various adverse events like infections, osteoporosis, avascular necrosis, cataracts and diabetes, contributing crucially to organ damage. 1 Consequently, the most recently updated European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of SLE advocate for using the lowest possible prednisone-equivalent GC dose (≤5.0 mg/day) and discontinuing use when feasible, emphasising the importance of GC-sparing agents, such as biologics or immunosuppressives.1


  • Open Access

    Validation of proposals for definitions of moderate and severe disease activity in SLE: impact on flares, quality of life, damage accrual, hospitalisations and mortality

    by Irene Altabás-González, Iñigo Rua-Figueroa, Karen Roberts, Ivonne Lourdes Mamani, Coral Mouriño, Julia Martinez-Barrio, Maria Galindo Izquierdo, Jaime Calvo-Alén, Celia Erausquin, Belén Serrano-Benavente, et al.

    Introduction: Accurate assessment of disease activity in SLE is crucial but challenging due to its varied clinical manifestations and severity. Current tools like the SLE Disease Activity Index (SLEDAI) have limitations, including unvalidated cut-off points, low sensitivity to certain severe features and an overemphasis on serological markers. There is a need for improved definitions of disease activity. Methods: We analysed data from 1463 patients with SLE in the prospective, multicentre RELESSER-PROS cohort (39 Spanish hospitals) over five annual visits. A panel of lupus experts used the Delphi method to develop new definitions for moderate disease activity state (MODAS) and severe disease activity state (SEDAS). These incorporated clinical SLEDAI (cSLEDAI), selected severe non-SLEDAI manifestations (eg, neuropsychiatric involvement, proteinuria, severe haematological features) and the Physician Global Assessment. We compared the predictive performance of MODAS/SEDAS with SLEDAI for mortality, organ damage, severe flares, hospitalisations and health-related quality of life, using receiver operating characteristics curves. Results: At baseline, 20% of patients met MODAS criteria and 24.6% SEDAS criteria, versus 10.5% and 3.0%, respectively, by SLEDAI. MODAS/SEDAS reclassified 19.9% of patients considered mild by SLEDAI, and 53.3% of moderate cases. MODAS/SEDAS showed modest but consistent improvement in predictive accuracy for damage (area under the curve 0.570 vs 0.550), flares (0.609 vs 0.564) and hospitalisations (0.609 vs 0.565). These definitions were associated with worse outcomes and demonstrated a dose–response relationship, although the overall predictive ability remained moderate. Conclusion: MODAS and SEDAS offer an alternative framework for defining moderate and severe SLE activity, with modest but consistent improvements in predictive performance compared with SLEDAI. By integrating cSLEDAI, key severe features and physician judgement, they improve prognostic performance and support a severity-based approach to clinical management and research. Their clinical utility remains preliminary, and further external validation is required before routine implementation.


  • Open Access

    Comorbidity clusters and their relationship with severity and outcomes of index diseases, in a large multicentre systemic lupus erythematosus cohort

    by Iñigo Rua-Figueroa, Natalia Pérez-Veiga, Esther Rodríguez-Almaraz, María Galindo-Izquierdo, Celia Erausquin, Antonio Fernandez-Nebro, Esther Uriarte Itzazelaia, Belén Serrano-Benavente, Jaime Calvo Alén, Sara Manrique-Arija, et al.

    Objective: Patients with SLE have a well-known increased risk of major comorbidities, although they are also very heterogeneous in terms of the prevalence of comorbid conditions. The relationships of such comorbidities with the outcomes and the severity of index diseases are less known. We aimed to evaluate the interactions between comorbid conditions, in a large multicentre SLE cohort, and their impact on severity and outcomes, using a cluster analysis. Methods: Data on 14 cumulative comorbidities were derived from patients with SLE (American College of Rheumatology (ACR)-97 criteria) who had been included in the retrospective phase of the RELESSER (Spanish Society of Rheumatology National Register of SLE). The Severity Katz Index and the SLICC/ACR Damage Index were calculated. Unsupervised cluster analysis was performed to better characterise the relationships between comorbidities in a large multicentre cohort of patients with SLE. For intercluster differences testing, analysis of variance and Tukey tests were used to compare continuous numerical variables; a Kruskal-Wallis test to discrete variables and the χ² (or Fisher’s exact test) were used for categorical ones. Results: A total of 3658 patients with SLE were included. Men accounted for 9.6% of patients. The mean (SD) age was 45.9 years, and 93% were Caucasian. Four clusters, with markedly different comorbidity profiles and outcomes, were identified: in cluster 2 (n=516), patients were grouped around depression (100% of the cases); in cluster 3 (n=418) around serious infections (100%); and in cluster 4 (n=388) around cardiovascular events (also 100%). However, in cluster 1, the largest one (n=2336), no patient had any of the three defining comorbidities of the other clusters, and this cluster was associated with the best outcomes. Conclusions: Cluster analysis identifies well-differentiated subsets of patients with SLE in terms of their comorbidities. The most relevant comorbidities in SLE tend to aggregate in the most severe patient subsets.